Targacept to Report First Quarter 2013 Financial Results on May 7, 2013

  Targacept to Report First Quarter 2013 Financial Results on May 7, 2013

Business Wire

WINSTON-SALEM, N.C. -- April 30, 2013

Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics™, today announced that it will report
financial results for the first quarter of 2013 on the morning of Tuesday, May
7, 2013, before the U.S. financial markets open.

Management will discuss the first quarter financial results, provide a
business and program update and discuss expectations for the future via
conference call at 8:30 a.m. Eastern Time on Tuesday, May 7, 2013. The
conference call may be accessed by dialing 866.515.2913 for domestic
participants and 617.399.5127 for international callers (reference passcode
92922085). A replay of the conference call may be accessed beginning
approximately two hours following the call on May 7, 2013 through May 21, 2013
by dialing 888.286.8010 for domestic callers and 617.801.6888 for
international callers (reference passcode 98152896).

A live audio webcast of the conference call will be accessible from the
Investor Relations page of Targacept’s website, www.targacept.com. To ensure a
timely connection to the webcast, it is recommended that users register at
least 15 minutes prior to the scheduled start time. An archived version of the
webcast will also be available for replay on the Investor Calendar section of
the Investor Relations page of Targacept’s website for at least two weeks
following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for
difficult-to-treat diseases and disorders of the nervous system. NNR
Therapeutics selectively modulate the activity of specific neuronal nicotinic
receptors, unique proteins that regulate vital biological functions that are
impaired in various disease states. Targacept’s clinical pipeline includes
multiple Phase 2 product candidates, all representing first-in-class
opportunities. Targacept leverages its scientific leadership and diverse
pipeline to attract significant collaborations with global pharmaceutical
companies. For more information, please visit www.targacept.com.


Building Health, Restoring Independence^®


Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Linnden Communications
Michelle Linn, 508-362-3087
Press spacebar to pause and continue. Press esc to stop.